BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on March 30, 2026.
The NDA includes interim Phase 3 FORTIFY data showing statistically significant, clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio anticipates U.S. approval and a launch in late 2026/early 2027, is seeking expedited paths in Europe, and notes prior Orphan Drug, Fast Track, and Rare Pediatric designations.
Positive
- FORTIFY met all pre-specified primary and secondary endpoints at the 12-month interim analysis
- Statistically significant improvements reported in ambulation and pulmonary function
- Favorable safety profile reported across interim Phase 3 data
- Regulatory designations: Orphan Drug, Fast Track, Rare Pediatric (FDA) and Orphan Drug (EMA)
- U.S. launch timeline anticipated in late 2026/early 2027 if approved
Negative
- NDA relies on 12-month interim FORTIFY data rather than a final, completed dataset
- Approval timing is anticipated, not guaranteed, dependent on FDA review and potential additional requests
- Priority Review/Priority Review Voucher eligibility is described as potential, not confirmed
News Market Reaction – BBIO
In the Mar 30 session, BBIO declined 0.49%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Scientific data presentation | Positive | +1.6% | Announcement of long-term ATTRibute-CM OLE data presentations at ACC meeting. |
| Mar 20 | Equity inducement grants | Neutral | +1.6% | New-hire RSU inducement grants under Nasdaq Rule 5635(c)(4). |
| Mar 11 | Phase 3 interim data | Positive | -3.9% | Positive Phase 3 FORTIFY interim data for BBP-418 in LGMD2I/R9. |
| Mar 04 | Upcoming data disclosure | Positive | +3.1% | Planned presentation of additional FORTIFY data at MDA conference. |
| Feb 24 | Earnings and pipeline update | Positive | -2.6% | Q4/FY 2025 results with strong Attruby sales and multiple planned NDAs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions have been mixed: positive clinical and scientific updates sometimes saw selling, while other data and event headlines drew modest gains.
Over the past months, BridgeBio reported multiple late-stage data and corporate milestones. On Feb 24, it delivered Q4 and full-year 2025 results with $502.1M in 2025 revenue and noted several planned NDAs. In early March, Phase 3 FORTIFY updates for BBP-418 in LGMD2I/R9 showed consistent efficacy and safety, yet the Mar 11 clinical readout saw a -3.94% reaction while a subsequent data-presentation notice on Mar 4 aligned with a 3.11% gain. Today’s NDA submission extends that clinical-to-regulatory progression.
Key Terms
new drug application regulatory
nda regulatory
fda regulatory
orphan drug regulatory
fast track regulatory
rare pediatric disease designation regulatory
priority review regulatory
priority review voucher regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function
- Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027
- If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD
PALO ALTO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced the submission of its New Drug Application (NDA) to the FDA for oral BBP-418 for the treatment of individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
“This NDA submission brings us one step closer to delivering the first approved therapy to individuals and families affected by LGMD2I/R9, a severe, progressive neuromuscular disease,” said Christine Siu, Chief Executive Officer of BridgeBio Neuromuscular. “This achievement not only reflects the strength of the data, but also our dedicated focus on addressing the urgency of a community that has long been waiting for meaningful treatment options. We are committed to working closely with the FDA to make this potential disease-modifying therapy available as quickly as possible.”
FORTIFY, the Phase 3 clinical trial of BBP-418, successfully met all pre-specified primary and secondary endpoints of its 12-month interim analysis. The topline results can be found here. Additional positive results demonstrating the rapid and consistent treatment effect and favorable safety profile of BBP-418 were presented earlier this month at the 2026 MDA Clinical and Scientific Conference in a late-breaking oral presentation, which can be found here.
BridgeBio anticipates a U.S. launch following FDA approval in late 2026/early 2027. If successful, BBP-418 would be the first and only approved therapy for individuals living with LGMD2I/R9, potentially representing the first approval of a therapy for any form of LGMD. The Company is also engaging regulatory agencies to identify an expedited path to approval for BBP-418 in Europe.
BBP-418 has previously received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the European Medicines Agency (EMA). With Fast Track designation and the potential for BBP-418 to address unmet need in LGMD2I/R9, the NDA for BBP-418 may be eligible for Priority Review. Consistent with Rare Pediatric Designation from the FDA, if BBP-418 is approved, BridgeBio may qualify for a Priority Review Voucher. The Company intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age and in LGMD2M/2U in the near future.
About Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
LGMD2I/R9 is a monogenic autosomal recessive disease caused by partial loss of function mutations in the fukutin-related protein (FKRP) gene, and FKRP mutations impair glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells. Clinical manifestations typically present as a skeletal myopathy affecting the lower and then upper limbs, which is commonly later accompanied by pulmonary muscle and cardiac muscle involvement. Individuals who harbor a homozygous L276I genotype typically develop disease manifestations during late childhood with progression to loss of independent ambulation (
About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include express and implied statements relating to the Company’s expectations regarding the regulatory review process, potential approval, and timing of a potential launch for BBP-418 in LGMD2I/R9; the Company’s expectations regarding the initiation and timing of clinical trials of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age and in LGMD2M/2U; the potential for BBP-418 to become the first and only approved therapy for LGMD2I/R9 and potentially the first approved therapy for any form of LGMD; the anticipated regulatory pathway for BBP-418; and the potential eligibility of BBP-418 for Priority Review and under the Rare Pediatric Disease Priority Review Voucher program, and the related FDA review timeline. Such statements reflect the Company’s current views about the Company’s plans, intentions, expectations and strategies, which are based on the information currently available to it and on assumptions the Company has made. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data, the design and success of ongoing and planned clinical trials, future regulatory filings, approvals and/or sales, despite having ongoing and future interactions with the FDA or other regulatory agencies to discuss potential paths to registration for the Company’s product candidates, the FDA or such other regulatory agencies not agreeing with the Company’s regulatory approval strategies, components of the Company’s filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
